No search results found. Try the button "Search complete website".
The Importance of DNA Screening
As the field of synthetic biology rapidly advances, the ability to synthesize DNA has become more accessible than ever. While this progress enables groundbreaking research in medicine, agriculture, and biotechnology, it also presents potential biosecurity challenges. The synthesis of genetic sequences—especially those that could be misused—requires responsible oversight.
This is where DNA screening plays a crucial role.
DNA screening ensures that synthesized sequences do not contain hazardous or potentially harmful genetic elements. By implementing proper screening processes, DNA synthesis providers can mitigate biosecurity risks, comply with regulatory standards, and foster trust within the scientific community.
DNA synthesis providers, including companies that manufacture oligonucleotides, plasmids, and gene fragments, must balance innovation with security. The misuse of synthetic DNA, whether intentional or accidental, can lead to significant risks. Several key factors highlight the need for robust screening protocols:
Ensuring that DNA sequences linked to known pathogens or harmful toxins are not inadvertently synthesized.
Meeting international biosecurity standards, such as those outlined by the U.S. Department of Health and Human Services (HHS), the EU, and the International Gene Synthesis Consortium (IGSC).
As technology progresses, companies have a duty to uphold ethical standards and contribute to a safer biotech ecosystem.
Demonstrating a proactive approach to biosecurity helps build trust among customers, regulators, and stakeholders.
At Biolegio, we recognize the importance of responsible DNA synthesis. That’s why we are actively exploring biosecurity measures to reinforce safety in oligonucleotide production. By integrating advanced screening tools, we aim to:
✅ Prevent the synthesis of potentially harmful genetic sequences
✅ Ensure compliance with global biosafety regulations
✅ Support researchers in conducting safe, ethical, and responsible experiments
✅ Strengthen trust and transparency within the biotech industry
To further improve the reliability of your experiments, we invite you to add your specific sequences to our screening database. This solution eliminates contamination risks and prevents primer binding errors, essential for high-precision applications like gene synthesis, diagnostics, and sequencing.
Our approach is not just about meeting compliance requirements—it’s about setting a higher standard for safety and integrity in DNA synthesis.
Several organizations and initiatives have emerged to enhance biosecurity in DNA synthesis. These efforts aim to develop privacy-preserving, scalable, and efficient screening tools:
To ensure a level playing field and build trust, Biolegio supports the establishment of a binding and harmonized framework for nucleic acid synthesis screening for all providers operating in the EU. This aligns with the long-standing efforts of the International Gene Synthesis Consortium (IGSC) to promote responsible and harmonized standards
As DNA synthesis technology continues to evolve, so too must the industry’s approach to biosecurity. Collaboration between researchers, regulators, and industry leaders is essential to ensuring that DNA synthesis remains a force for good in science and medicine. Stronger screening measures, increased awareness, and technological advancements will help safeguard the future of biotechnology.
At Biolegio, we are excited to be part of this important conversation. What are your thoughts on DNA screening and biosecurity?
Join us in discussing how we can shape a safer and more responsible future for synthetic biology.
Biolegio B.V. -Framework Attestation Statement -May 2025
Biolegio B.V. understands that United States federally funded life sciences entities and funding agencies are relying on this attestation prior to purchasing gene synthesis equipment or gene synthesis products.
Biolegio B.V. self-attests to complying with the US Framework for Nucleic Acid Synthesis Screening.
Should this information change, Biolegio B.V. agrees that it will update this statement within 72 hours.
For more information, please contact info@biolegio.com.